Shape Memory Medical Raises $10 Million to Advance First Randomized Pivotal Trial of Aneurysm Sac Embolization After EVAR
核心洞察
Shape Memory Medical (搜索) closed a $10 million convertible note financing led by August Global Partners (搜索), with Taiwania Capital (搜索) also participating as a new investor.
The funding supports the AAA-SHAPE Pivotal Trial, the first randomized controlled pivotal trial testing proactive aneurysm sac embolization at the time of endovascular aneurysm repair (EVAR).
AAA-SHAPE randomized 180 patients 2:1 across 48 centers in the U.S., Europe, and New Zealand, with primary endpoints of 30-day safety and at least 10% sac volume reduction without AAA-related reintervention at one year.
Shape Memory Medical (搜索) has closed a $10 million convertible note financing to advance clinical development of its shape memory polymer technology for aortic disease. New investor August Global Partners (搜索) led the financing, with Taiwania Capital (搜索) also participating as a new investor. The company is additionally backed by healthcare investors including HBM Healthcare Investments (搜索), Earlybird Venture Capital (搜索) and WexMed II (搜索).
The capital will support continued patient follow-up and data collection in Shape Memory Medical (搜索)'s AAA-SHAPE Pivotal Trial and advancement of its FLAGSHIP feasibility study.
A First-of-Its-Kind Randomized Pivotal Trial
Endovascular aneurysm repair (EVAR) has transformed the treatment of abdominal aortic aneurysms by offering many patients a less invasive alternative to open surgery. But EVAR also leaves behind a problem that has never been fully solved: the aneurysm sac remains in place. In many patients, that sac never shrinks. In some, it grows, raising concern about future rupture risk.
Shape Memory Medical (搜索)'s AAA-SHAPE Pivotal Trial, which completed enrollment on July 7, 2026, is the first randomized controlled pivotal trial to directly test whether proactive aneurysm sac embolization at the time of EVAR can change that pattern. The trial randomized 180 patients 2:1 across 48 centers in the United States, Europe, and New Zealand, with follow-up planned through five years. Primary endpoints include 30-day safety and the proportion of patients achieving at least 10% aneurysm sac volume reduction without AAA-related reintervention at one year.
AAA-SHAPE is evaluating the safety and effectiveness of the company's IMPEDE-FX RapidFill (搜索) Device when used alongside endovascular aneurysm repair to proactively manage the abdominal aortic aneurysm (搜索) sac.
Why Sac Non-Regression Matters
Mary Dennehy, Vice President of Marketing at Shape Memory Medical (搜索), who spent years at Endologix working in endovascular aneurysm repair, explained the clinical challenge: "Physicians are often left watching the sac over time and hoping it will regress. If it does not, the options are limited, inconsistent, and usually reactive."
A common cause of sac non-regression is Type II endoleak, which occurs when blood continues to flow into the aneurysm sac through small blood vessels arising from the aneurysm sac. However, Dennehy emphasized that the issue extends beyond endoleaks: "Some patients have type II endoleaks that prevent the aneurysm from shrinking. Other patients have no visible endoleak, yet the sac still fails to regress. The reasons are multifactorial."
The consequence that resonates most with physicians, according to Dennehy, is the recognition that a sac that does not regress is not necessarily a benign finding. Sac non-regression represents uncertainty, meaning continued surveillance, additional CT imaging with radiation exposure, and the potential for rehospitalization or secondary procedures.
A Distinct Aortic Application
Ted Ruppel, President and CEO of Shape Memory Medical (搜索), noted that while the underlying shape memory polymer technology may be familiar to physicians, using IMPEDE-FX RapidFill (搜索) to embolize the aneurysm sac during EVAR is a distinct application involving different anatomy, clinical objectives, procedural considerations, and potential risks. IMPEDE-FX RapidFill remains investigational for the aortic indication and is not cleared or approved for that use in the United States.
The randomized design is important because sac behavior after EVAR can be influenced by many factors, including anatomy, thrombus burden, device choice, endoleaks, and patient-specific healing. "A randomized trial gives the field a much cleaner way to evaluate whether adjunctive sac embolization itself changes outcomes, rather than relying only on retrospective comparisons or single-arm experience," Ruppel said.
Shape Memory Medical (搜索)'s polymer technology uses a low-density, highly porous embolic material delivered through a catheter in compressed form. The material self-expands upon contact with blood and is designed to promote organized thrombus formation, adapt to complex vascular anatomy and preserve radiolucency for follow-up imaging.
The Importance of Sac Volume Reduction
Mary Dennehy explained why the endovascular community will focus on sac volume reduction specifically when results are published. Historically, the standard measurement to assess changes in sac size has been diameter, largely because tools for measuring aortic sac volume have not always been practical, automated, or easy to use. With improved software, and increasingly with AI-enabled tools, volume measurement is becoming more feasible. "Volume is the more sensitive and complete measure of sac behavior," she said.
"The most persuasive result will likely be consistency across endpoints," Dennehy added. "If those signals align, it becomes a much stronger clinical story than any single endpoint on its own." The company is also collecting patient quality-of-life data to evaluate whether there is a meaningful difference between patients whose sacs shrink and those whose sacs do not, including differences in anxiety, state of mind, and how they feel about their treatment overall.
FLAGSHIP Feasibility Study
The financing will also support advancement of the FLAGSHIP feasibility study, a first-in-human trial evaluating Shape Memory Medical (搜索)'s investigational False Lumen Embolization System for treating the false lumen associated with aortic dissection (搜索). That study is designed to evaluate safety and preliminary signs of efficacy and will follow patients for two years.
A Potential Shift in Clinical Practice
Ted Ruppel framed the long-term vision: "Five years from now, success would mean that these patients have a more durable EVAR result with fewer late-stage problems. Ideally, their aneurysm sacs have regressed, they have avoided repeat procedures, and their physicians have much greater confidence that the aneurysm has stabilized."
"If the trial is successful, it could shift the conversation from managing sac failure after EVAR to preventing it at the time of EVAR," Ruppel said. "That would be a meaningful change for physicians, patients, hospitals, and the healthcare system because the downstream burden of surveillance, uncertainty, secondary intervention, and late aneurysm-related events is substantial."
Shape Memory Medical (搜索)'s products have received regulatory approvals in more than 40 countries, and its technology has been used in more than 3,500 patients worldwide. IMPEDE-FX RapidFill (搜索) remains investigational in the U.S.
"With enrollment recently completed in our AAA-SHAPE Pivotal Trial and continued progress in FLAGSHIP, we are focused on generating the clinical evidence needed to support the broader adoption of our shape memory polymer technology in aortic applications," Ruppel said. "With AAA-SHAPE fully enrolled and FLAGSHIP advancing, the company is at an inflection point, and the data ahead will define it."